src<"http://pagead2.googlesyndication.com/pagead/show_ads.js">
Google

1/29/2009

Sold EBS at 22.95 and LPHI at $39

I took small losses in EBS and LPHI today due to personal reasons. These two stocks are better picks in today's turbulent markets, and I suggest that you keep them on your radar. The only reason I decided to sell, was to free-up capital to fund personal endeavors.

Recently, I have changed careers to become a Financial Advisor for a strong financial institution. You may ask, "what financial instution is strong these days?" The answer is to think "private". Financial institutions that are private do not succumb to short-term results, therefore they do not gamble on earnings like public financial corporations. That being said, I decided to change careers in order to realize my true-calling - which is comprehensive financial planning. My goal is to meet with clients/prospects and determine their financial goals. After reviewing their goals versus their real situation, I will make relevant suggestions that will increase the likelihood that they will achieve (and most likely, surpass their goals).

P.S. Send an email to richardbrinker@hotmail.com if you live in Georgia and would like to speak...

1/07/2009

Sold SCO at $29.15 and Bought LPHI at $43.71

I sold SCO today for a gain of 20% from my purchase two days ago. Oil prices will likely continue lower, but I couldn't resist taking a two-day gain that large. LPHI is a great stock, in my opinion. This stock fits my criteria of not being sensitive to the market, has a bullish chart, and a clean Balance Sheet (along with EBS and FRPT).

1/06/2009

Covered Short Position in MAXY at $9.25

I set a stop at $9.23 for MAXY - which was a new 52-week high. Took a loss of 4%, but it only represented a small portion of my holdings. I learned an easy lesson, don't short stocks near their 52-week highs - Duh...

1/05/2009

Sold TBT at $41, Bought SCO at $24.72, Shorted MAXY at $8.87

I made a few moves today that I hope will play out well. I took profits in TBT for a 12% gain, and bought SCO in hopes that crude oil will resume its downward trend. MAXY seems to be a decent short here, but I may be forced to cover at $9.23 if it gets to that level. MAXY seems to be topping, and doesn't have much positive news ahead of it. The company develops drugs from currently approved drugs and has sold its recent discovery. MAXY has enough cash on hand to get through about 2 years of operations if they don't develop a new drug to sell-off to another company.

1/03/2009

Market Strategy

As we all have seen in the past 12-18 months, stocks have been very volatile and nearly impossible to gauge where the over-all markets are heading. That being said, I have been on the look-out for stocks that have zero correlation to the stock market and economy. These stocks rise/fall based on their own success or failures, and over-all trends. Two stocks that I have been following are FRPT and EBS. These both have the desired characteristic of bucking the market's trend.

Please let me know of any stocks that you follow that meet the criteria below by commenting on this article:

-Zero Correlation to the market.

-Zero Debt.

-Bullish trend for stock chart.

-High probability of increasing earnings.

1/02/2009

Sold FRPT at $6.49 and Bought EBS at $25

I decided to cash-in on FRPT for a 20% gain in a week. FRPT should continue to do well in this market, but I feel it has room for a pullback. Emergent BioSolutions (EBS) is another good play considering the characteristics below:

-Zero correlation with the rest of the market.

-Zero Debt.

-Chart is bullish.

-Strong Cash Flow.

-Effective Management.

-New drugs in pipeline.

-Perfectly clean Balance Sheet (no "Goodwill" or "Intangibles")

12/26/2008

Sold DXO at $1.90 and Bought FRPT at $5.35

I took a steep 23% loss in DXO and bought FRPT with the proceeds. This was a painful loss, but I hope to learn a lesson to cut losses earlier. My hope is that I can more than make up for the loss with FRPT. The stocks seems to continuously move higher despite the rest of the market.